Between January and June 2018, Russia produced 157.4 bln RUB worth of pharmaceutical drugs (dispatch prices, VAT included), which is in monetary terms 1.2% lower than that of the same period of 2017. In physical terms, Russia produced 2 bln units of pharmaceuticals over the period, which is 10% lower than that of the same period of 2017. If calculated in minimum dosage units (MDU), the dynamics are +0.6%. The dynamics of the production of over-the-counter drugs in physical terms are -9%, while those of the Rx production are -11%. In June, the dynamics of the OTC production were +4.5%, while those of the Rx production were -19%.

Among the top 10 EphMRA groups of level two with the highest dispatch volume of OTC drugs in physical terms, 7 have negative dynamics. Antivirals, painkillers and cough and cold medicines are among the worst, with -32%, -19% and -15%, respectively. Nose medicines have the highest dynamics in the groups with a sales increase, especially Oxyfrin (Groteks) and Evamenol (Moscow Pharmaceutical Factory), with a 47% increase.

As for Rx drugs, the following categories have the lowest dynamics: solutions for intravenous admission (-50%), anti-infective drugs (-19%), and anti-inflammatory and anti-rheumatics drugs (-15%). Nevertheless, the production of beta-adrenoblockers has very good dynamics (+52%), in particular Sotalol (Canonpharma Production) (+100%) and Nebivolol (Severnaya Zvezda) (+56%.)

Dynamics of pharmaceutical drug production in Russia, including production of pharmaceuticals of foreign companies on owned or contract plants, in physical (units) and monetary terms (RUB, VAT included) (January 2017 – June 2018)